Freely Filtered, a NephJC Podcast

The Filtrate: Joel Topf Swapnil Hiremath Priya Yenebere Nayan Arora With Special Guest: Brendon Neuen Super smart guy and clinical trialist Michelle Rheault Lead author of DUPLEX and friend of the pod Show Notes Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis NephJC Summary | PubMed | NEJM KDIGO FSGS Guidelines 2021 (PDF) Characterization of the Clinical Evidence Supporting Repository Corticotropin Injection for FDA-Approved Indications, A Scoping Review (JAMA Internal Medicine) DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS (PubMed) Vlado Perkovic, mentor and sponsor extradenoire (UNSW Sydney) Shimer Its a floor wax and a desert topping (TikTok) SONAR: Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease: a double-blind, randomised, placebo-controlled trial. (NephJC) Travere Therapeutics Announces FDA Accelerated Approval of FILSPARIᵀᴹ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy (Travere press release) GFR Slope: Chronic vs Total slope: A meta-analysis of GFR slope as a surrogate endpoint for kidney failure (Nature Medicine) There are dozens of us! Dozens! (Know your Meme) Brendon’s Neuen’s tweet about total versus chronic slope (X | Twitter) Julie R. Ingelfinger, deputy editor for the New England Journal of Medicine (Wikipedia) You know nothing, John Snow (YouTube shorts) Tubular Secretions Swapnil Foundation season two on Apple TV Wheel of Time season two Amazon Prime Brendon Andor Priya Poverty, by America Mattew Desmond Nayan The Armor of Light: A Novel by Ken Follett Michelle Lessons in Chemistry: A Novel by Bonnie Garmus

The Filtrate: Joel Topf Swapnil Hiremath Jordy Cohen AC Gomez With Special Guest: Tim Anderson @TimAndersonMD Editor: Priya Yenebere Show Notes Clinical Outcomes of Intensive Inpatient Blood Pressure Management in Hospitalized Older Adults NephJC Summary | PubMed | JAMA Internal Medicine The Jordy AC collab: An Interactive Ambulatory Nephrology Curriculum for Internal Medicine Interns: Design, Implementation, and Participant Feedback (PubMed) Clinical Outcomes After Intensifying Antihypertensive Medication Regimens Among Older Adults at Hospital Discharge (PubMed) Trends in Blood Pressure Treatment Intensification in Older Adults With Hypertension in the United States, 2008 to 2018 (PubMed) Overlap Weighting: A Propensity Score Method That Mimics Attributes of a Randomized Clinical Trial (JAMA Guide to Statistics and Methods) Tubular secretions Swap The Dispatcher by John Scalzi (Wikipedia) AC A Heart that Works by Rob Delaney (NYT Review) Tim Demon Copperhead by Barbara Kingsolver (Amazon) Jordy The Anthropocene Reviewed: Essays on a Human-Centered Planet (Amazon) Joel The Dolomites for hiking n Northern Italy

Animal House Region NephMadness description by Tiffany Truong Editorial by Kelly Hyndman @DrKeeksPhD They May Look Cute, But Are All Animals Sweet? The Filtrate: Joel Topf Swapnil Hiremath Sophia Ambruso Josh Waitzman With Special Guest: Kelly Hyndman Editor: Sophia Ambruso Show Notes Animal House 2018 with Mark Zeidel, MD (AJKDblog) Animal House 2021 with Kelly Hyndman (AJKDBlog) Animal House 2022 with Kelly Hyndman (AJKDBlog) Mount Desert Island Summer Junket (Website) First person account go a Gila Monster bite (YouTube) Looks like Gila Hank, the gun toting mascot of Eastern Arizona College has been replaced by a non-gun toting Gila monster cowboy. Old logo (Reddit) | New logo (Gila Valley Central Newspaper) Discovery, characterization, and clinical development of the glucagon-like peptides (Drucker JCI 2017) The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease (Rossing NDT 2023) Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial (Novo Nordisk) King Gizzard & The Lizard Wizard - Gila Monster (YouTube) Eastern Arizona Campus Store Tubular Secretions Swap: Three Body Problem (Wikipedia) Josh: Animal Crossing (Nintendo) Sophie: Pyelonephritis in inflammatory bowel disease. Is this a thing? Joel: Maggie Moore(s) (Wikipedia)

How Medicine Works, and When It Doesn’t Amazon The Filtrate: Joel Topf Josh Waitzman Jennie Lin With Special Guest: Jade Teakell Perry Wilson Editor: Joel Topf Show Notes Understanding Medical Research: Your Facebook Friend is Wrong. Coursera Illusory truth effect (Wikipedia) Number needed to treat (Wikipedia) NNT at MedPage Today: NNT on NephJC Deaths of Despair: Suicide (CDC 2001-2021) Drug Overdose (CDC 2001-2021) Steve Jobs delayed therapy for his treatable pancreatic cancer (ABC News) Residents are unionizing at Mass General Brigham. Here's what you need to know (WBUR) Pi and bouncing bricks (YouTube) Doctors in New Zealand—the only non-U.S. country that allows DTC advertising—call for bans (FiercePharma) The Surgisphere Scandal: What Went Wrong? (The Scientist) VITAL SIGNS: FERTILITY; A Study Links Prayer and Pregnancy (The New York Times) Researcher Pulls His Name From Paper on Prayer and Fertility (The New York Times) Tubular Secretions Josh: Glomerular Nephritis by Thomas Addis (Review in JAMA from 1948) Jennie: The Chicago Marathon Jade: The People’s Hospital (Amazon) Perry: Anathem by Neal Stephenson (Amazon)

The Filtrate: Joel Topf Nayan Aurora Sophia Ambruso With Special Guest: Michael Collins Editor: Nayan Aurora Show Notes: Twitter is now X (NYT) Michael Collins (the astronaut, not the real one) PlasmaLyte by Baxter NephJC BEST Fluids summary Early Goal Directed Therapy for Sepsis NEJM manuscript which changed practice patterns and welcomed in an era of massive fluid resuscitation. PLUS Trial NEJM SPLIT Trial JAMA BaSICS NephJC Summary SALTED and SMART NephJC Summary Adaptive minimization wikipedia BEST Fluids statistical plan BEST Fluids in CLinicalTrials.gov Delayed Graft Function review in American Journal of Transplant Balanced Crystalloids versus Saline in Critically Ill Adults — A Systematic Review with Meta-Analysis in NEJM Evidence A pragmatic, open-label, randomized controlled trial of Plasma-Lyte-148 versus standard intravenous fluids in children receiving kidney transplants (PLUTO) in Kidney International Tubular Secretion Nayan finally getting around to Succession on HBO Sophia autoimmune protocol diet Hawthorne Effect Michael Stephen Fry reading Harry Potter

The Filtrate: Joel Topf Swapnil Hiremath Sophia Ambruso AC Gomez Josh Waitzman Jennie Lin Nayan Arora The Curbsiders Matt F. Watto (@DoctorWatto) Paul Nelson Williams, America’s primary care physician (@PaulNWilliamz) With Special Guest: JD Foster (@KidneyVet) Sayed Tabatabai (@TheRealDoctorT) Nephrologist in Austin and the author of These Vital Signs Michelle Rheault (@rheault_m) Chief of Pediatric Nephrology at the University of Minnesota and lead author of the DUPLEX Trial Editor: Joel Topf Show Notes: Lily toxicity in the cat (PubMed) Surgeons perform kidney transplants in cats amid rising demand for advanced pet care (ABC News) Treatment of ibuprofen toxicity with serial charcoal hemoperfusion and hemodialysis in a dog (PubMed) Nephrology in Veterinary Medicine (Kidney 360) Star Wars Society of San Antonio (FaceBook) These Vital Signs (Amazon) Dr Tabatabai read a short story called The Handholder, here is the original tweet thread for that story (ThreadReader) The pearl not the patient (PubMed) Late Braking and High Impact Clinical Trial press release MENTOR, Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy, was in 2019 not 2017 (NEJM) KALM-1, A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus, was in 2019 not 2017 (NEJM) Sophie’s number one pick: Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial (Lancet) Patients in the sparsentan group had a slower rate of eGFR decline than those in the irbesartan group. eGFR chronic 2-year slope (weeks 6–110) was −2·7 mL/min per 1·73 m2 per year versus −3·8 mL/min per 1·73 m2 per year (difference 1·1 mL/min per 1·73 m2per year, 95% CI 0·1 to 2·1; p=0·037); total 2-year slope (day 1–week 110) was −2·9 mL/min per 1·73 m2 per year versus −3·9 mL/min per 1·73 m2 per year (difference 1·0 mL/min per 1·73 m2 per year, 95% CI −0·03 to 1·94; p=0·058). Clinical Trial Considerations in Developing Treatments for Early Stages of Common, Chronic Kidney Diseases: A Scientific Workshop Cosponsored by the National Kidney Foundation and the US Food and Drug Administration (AJKD) AC Gomez’s Pick: MDR-101-MLK Update: Operational Immune Tolerance Achieved in Living Related HLA-Matched Kidney Transplant Recipients (ASN-Online.org) Josh’s Pick: A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy (NEJM) Nayan’s Pick: The EnAKT LKD Cluster Randomized Clinical Trial (JAMA Internal Medicine) The Freely Filtered simultaneous release (NephJC) Freely Filtered is now a verb. Swap’s Pick: Strategies for the Management of Atrial Fibrillation in PatiEnts Receiving Dialysis (SAFE-D) (ASN-Online.org) Joel’s Pick: AYAME Study: Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Bardoxolone Methyl in Diabetic Kidney Disease (DKD) Patients (ASN-Online.org) Reata is a no-show to the 2012 ASN Kidney Week (PBFluids) Michelle’s Pick: Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis. The DUPLEX Study (NEJM) DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS (PubMed)

The Filtrate: Joel Topf Swapnil Hiremath Sophia Ambruso AC Gomez With Special Guest: Amit Garg (@AmitXGarg) Nephrologist at Western University, London, and lead PI of the EnAKT LKD trial. Susan Q. McKenzie (LinkedIn) Co-Founder & Chair, Transplant Ambassador Program. President of the Kidney Patient and Donor Alliance of Canada. Editor: Joel Topf Show Notes: Late Braking and High Impact Clinical Trial press release JAMA Internal Medicine MyTEMP trial Personalised cooler dialysate for patients receiving maintenance haemodialysis (MyTEMP): a pragmatic, cluster-randomised trial (PubMed | NephJC | Freely Filtered) Transplant is cheaper! An economic assessment of contemporary kidney transplant practice (PDF) Transplant is better! Survival for waitlisted kidney failure patients receiving transplantation versus remaining on waiting list: systematic review and meta-analysis (PubMed) Transplant disparities Association of Race and Ethnicity With Live Donor Kidney Transplantation in the United States From 1995 to 2014 (PubMed) MUC1 Kidney Disease Autosomal Dominant Tubulointerstitial Kidney Disease: An Emerging Cause of Genetic CKD (Kidney International Reports) This study has all the adjectives: “We conducted a pragmatic, two-arm, parallel-group, open-label, registry-based, superiority, cluster- randomized clinical trial.” Explore Transplant by Amy Waterman, PhD Transplant Ambassador Program Kidney Failure Risk Equation A Predictive Model for Progression of Chronic Kidney Disease to Kidney Failure (JAMA | Calculator) The complete protocol A Quality Improvement Intervention to Enhance Access to Kidney Transplantation and Living Kidney Donation (EnAKT LKD) in Patients With Chronic Kidney Disease: Clinical Research Protocol of a Cluster-Randomized Clinical Trial (PDF) Pre-published statistical plan Enhance Access to Kidney Transplantation and Living Kidney Donation (EnAKT LKD): Statistical Analysis Plan of a Registry-Based, Cluster-Randomized Clinical Trial (PubMed) Hawthorne effect (Wikipedia) The Advancing American Kidney Health Initiative “Aim for 80% of new American ESRD patients in 2025 receiving either home dialysis or a transplant” (NKF) Tubular Secretions Swapnil The Time Travelers Wife by Audrey Niffenegger (Wikipedia) and HBO movie of the same name (Wikipedia). Sophia The Wheel of Time streaming on Amazon (Wikipedia) based on the series of books of the same name by Robert Jordan and Brandon Sanderson. Susan The Woman Who Loved Giraffes movie (Website) Amit Canadians cannot get Visas to visit India (Reuters) AC Eagles are good at Football (Fox Sports) and Alport Connect Meeting in San Diego (Alport Syndrome Foundation Website) Joel Live podcast recording at Kidney Week (NephJC)

The Filtrate: Joel Topf Jennie Lin Josh Waitzman With Special Guest: AC Gomez MedPeds nephrology fellow at Mass General/Brigham and Boston Children’s | Twitter Gentian Hall Assistant Professor of Medicine Duke Department of Medicine Editor: Sophia Ambruso Show Notes: APOL1 review by the OG Scientists APOL1 Nephropathy: From Genetics to Clinical Applications MYH9 and APOL1 connection: The population genetics of chronic kidney disease: insights from the MYH9–APOL1 locus Martin Pollack Lab Vertex Lab Worldwide Frequencies of APOL1 Renal Risk Variants (NEJM) Kidney Disease-Associated APOL1 Variants Have Dose-Dependent, Dominant Toxic Gain-of-Function End-Stage Renal Disease in African Americans With Lupus Nephritis Is Associated With APOL1 Apolipoprotein L1 Risk Variants Associate with Systemic Lupus Erythematosus-Associated Collapsing Glomerulopathy HEK293 Cells Wikipedia Tubular Secretions Josh: From Serial and the New York Times: The Retrievals Jennie: Marathon induced hyponatremia (NEJM) Donate to the NKF of Illinoise in honor of Jennie’s really long run Donate to New England Donor Services in honor of Josh’s much shorter ruin Gentian: Vivien Thomas wikipedia. HBO Movie: Something the Lord Made AC: Talking to the FDA about SGLT2i Tweet Joel: NephJC 2023 Fund drive

Bicarbonate did not slow the loss of GFR in this well done Swiss, single-blind study of transplant patients. The Filtrate: Joel Topf Nayan Arora Swapnil Hiremath Pirya Yenebere With Special Guest: Nav Tangri nephrologist and epidemiology at the University of Manitoba Editor: Nayan Arora Show Notes: Arsenal FC The London study that kicked it all off! de Brito-Ashurst, I., Varagunam, M., Raftery, M. J., & Yaqoob, M. M. (2009). Bicarbonate supplementation slows progression of CKD and improves nutritional status. Journal of the American Society of Nephrology: JASN, 20(9), 2075–2084. The multi center (but unblinded) UBI Study with mortality benefit! Di Iorio, B. R., Bellasi, A., Raphael, K. L., Santoro, D., Aucella, F., Garofano, L., Ceccarelli, M., Di Lullo, L., Capolongo, G., Di Iorio, M., Guastaferro, P., Capasso, G., & UBI Study Group. (2019). Treatment of metabolic acidosis with sodium bicarbonate delays progression of chronic kidney disease: the UBI Study. Journal of Nephrology, 32(6), 989–1001. The BiCARB Study: Double blinded and negative BiCARB study group. (2020). Clinical and cost-effectiveness of oral sodium bicarbonate therapy for older patients with chronic kidney disease and low-grade acidosis (BiCARB): a pragmatic randomised, double-blind, placebo-controlled trial. BMC Medicine, 18(1), 91. The initial Veverimer Study Wesson, D. E., Mathur, V., Tangri, N., Stasiv, Y., Parsell, D., Li, E., Klaerner, G., & Bushinsky, D. A. (2019). Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension. In The Lancet (Vol. 394, Issue 10196, pp. 396–406). doi.org/10.1016/s0140-6736(19)31388-1 The Valor CKD trial is still unpublished. But here is the press release. VALOR-CKD design manuscript The study of the night: Sodium bicarbonate for kidney transplant recipients with metabolic acidosis in Switzerland: a multicentre, randomized, single-blind, placebo-controlled, phase 3 trial NephJC | PubMed | Lancet Alkali with normal bicarb? Sure, take a look at: Goraya, N., Simoni, J., Jo, C., & Wesson, D. E. (2012). Dietary acid reduction with fruits and vegetables or bicarbonate attenuates kidney injury in patients with a moderately reduced glomerular filtration rate due to hypertensive nephropathy. Kidney International, 81(1), 86–93. Metforminator! The BASE Trial: Raphael, K. L., Isakova, T., Ix, J. H., Raj, D. S., Wolf, M., Fried, L. F., Gassman, J. J., Kendrick, C., Larive, B., Flessner, M. F., Mendley, S. R., Hostetter, T. H., Block, G. A., Li, P., Middleton, J. P., Sprague, S. M., Wesson, D. E., & Cheung, A. K. (2020). A Randomized Trial Comparing the Safety, Adherence, and Pharmacodynamics Profiles of Two Doses of Sodium Bicarbonate in CKD: the BASE Pilot Trial. Journal of the American Society of Nephrology: JASN, 31(1), 161–174. Tubular Secretions Swap The Three-Body Problem (novel) | Netflix Nayan Women’s World Cup Tangri English Premier Soccer and Inflation Priya Silo on Apple TV Joel Live Podcast recording at ASN Kidney

The Filtrate: Joel Topf Nayan Arora Sophia Ambruso With Special Guest: Boback Ziaeian @boback Assistant Professor of Medicine David Geffen School of Medicine at UCLA. His Google Schoolar page is better than yours. And returning for her fourth time (why do we keep inviting her back?) Sadiya Khan @heartDocSadiya Assistant Professor of Medicine (Cardiology) and Preventative Medicine at Northwestern Feinberg School of Medicine. Link Editor: Priya Yenebere Show Notes: Diuretic Therapy review by. Craig Brater NEJM The manuscript in JAMA | NephJC Metoprolol vs Carvedilol: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial (Lancet) EMPULSE: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial (Nature Medicine) Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure The ASTRONAUT Randomized Trial Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure The EVEREST Outcome Trial Sophia ended up placing fifth in NephMadness 2023. (Link) Joel finished 697th After winning in the opening round, Northwestern lost to UCLA, in the second round of the March Madness tournament, 68-63. Torsemide to furosemide equivalents CardioMems positive trial: Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial (The Lancet) CardioMems negative trial: Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial (The Lancet) Estimation of the Absolute Risk of Cardiovascular Disease and Other Events: Issues With the Use of Multiple Fine-Gray Subdistribution Hazard Models (Circulation) Torasemide in chronic heart failure: results of the TORIC study (PubMed) Tubular Secretions Nayan: Louise Penny A World of Curiosities: A Novel (Amazon) Sadiya: Ted Lasso season three Sophia:The Last of Us on HBO and SNL skit Mario Cart as Prestige Drama Boback: Duolingo for Japanese

The Filtrate: Joel Topf Swapnil Hiremath Josh Waitzman Nayan Arora Sophia Ambruso With Special Guest: Megan Prochaska Assistant professor of medicine at University of Chicago John Asplin Medical Director Consultant LithoLink (Twitter) Editor: Joel Topf Show Notes: The LithoLink website Stone Camp tweet Prevention of Repeated Episodes of Kidney Stones in Adults: A Clinical Practice Guideline From the American College of Physicians (link) NOSTONE in the NEJM and NephJC Fred Coe Google Scholar | YouTube | Blog Hypercalcuria. Curhan et al. 24-h uric acid excretion and the risk of kidney stones PubMed EQUIL2 software to evaluate urinary super saturation Anna Zisman Racial Differences in Risk Factors for Kidney Stone Formation (CJASN) Potassium Citrate on GoodRx Moonstone Nutrition Potassium and citrate by Fred Coe (blog) Thiazide Diuretics and Fracture Risk: A Systematic Review and Meta‐Analysis of Randomized Clinical Trials (PubMed) Chlorthalidone promotes mineral retention in patients with idiopathic hypercalciuria by Coe et al (PubMed) NHANES 24-hour urine Na (Abstract) Kidney Stone risk is reduced with empagliflozin (PubMed) Prospective trial to determine the effect of SGLT2i on urinary supersaturation (BMJ Open) GLP agonists and kidney stone risk Tubular Secretions Swap: Star Wars: Thrawn Series by Timothy Zahn (Penguin Random House) Josh: Little League Megan: Renal related podcasts Sophia Renal Stone Camp and ABCKidney.com Nayan: Ted Lasso Robert Galbraithand The Comoran Strike Novels (home page) John: Fred Coe’s Blog Joel: Spiderman across the Spider-Verse (Wikipedia)

The Filtrate: Joel Topf Swapnil Hiremath Josh Waitzman Jordy Cohen With Special Guest: Areef ishani lead author and Chief of Medicine VA Minneapolis Editor: Nayan Arora Show Notes: MRFIT switches diuretics and finds better outcomes. Swapnil shows how many studies he is familiar with by spewing out a string of them. Chlorthalidone wins: ALLHAT, MRFIT, SPRINT, HYVET, CLICK (not mentioned by Swap but by Jordy later) HCTZ loses: HOPE3, ACCOMPLISH Diuretic half-lifes NEJM review Edarbyclor: Azilsartan and Chlorthalidone $240/month as per GoodRx Nice mention of late study originator Frank Lederle. Please see his article in Annals about his diagnosis of pancreatic cancer. Moving. Network analysis of HCTZ vs chlorthalidone Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil by George Bakris Synopsis of the 2020 U.S. Department of Veterans Affairs/U.S. Department of Defense Clinical Practice Guideline: The Diagnosis and Management of Hypertension in the Primary Care Setting (Annals of Internal Medicine) Testing for Primary Aldosteronism and Mineralocorticoid Receptor Antagonist Use Among U.S. Veterans: A Retrospective Cohort Study by Jordy Cohen Study showing better risk reward ratio of low dose than high dose thiazide diuretics. Treatment of hypertension in the elderly: I. Blood pressure and clinical changes. Results of a Department of Veterans Affairs Cooperative Study. Tubular Secretions Swapnil Louise Penny author of book upon which the Amazon Prime series, Three Pines is based on. Jordy Last of Us series on HBO Josh Channel Your Enthusiasm A Very Special Episode: Meet the Glaucomfleckens Areef The Body: A Guide for Occupants Joel NephMadness (this did not age well)

The Filtrate: Joel Topf Swapnil Hiremath Josh Waitzman Sophia Ambruso With Special Guest: Anna Vinakova Associate Professor of Medicine at Virginia Commonwealth University. NephMadness Executive. Vanuja Java is a transplant nephrologist at Washington University in St. Louis, MO. Her research involves functional characterization of genetic variants in complement-mediated diseases. She co-chairs the ClinGen complement gene curation expert panel. Editor: Sophia Ambruso Show Notes: #NephMadness 2023: Thrombotic Microangiopathy Region TMA Review article in the NEJM from 2014: Syndromes of Thrombotic Microangiopathy Dr. Anuja Java Co-chairs Working Group in an International Committee for Revising aHUS Nomenclature Nephrology Secrets 4th Edition at Amazon University of Iowa Genetic testing for aHUS Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study. KI reports. This is the Netherlands study. They used home urine dipsticks to monitor for relapses. Clinical promise of next-generation complement therapeutics Nature reviews. Drug Discovery NephMadness Podcrawl Tubular Secretions Swap: Neuromancer and the works of William Gibson (@GreatDismal) Sophia: The Magicians on Netflix Anna: Recommends nephrology. Says it is awesome. Anuja: Dope Sick on Hulu and Women in Nephrology mentor program Josh: Mobituaries with Mo Rocca. Specifically “Death of a Banana” Joel: Ivory by TapBot

Welcome to the NephMadness PodCrawl The idea behind a podcrawl is for a variety of podcasts to coordinate on timing and topic to push a theme and get each other’s listeners to explore all of the podcasts. One of the first goals behind NephMadness was to build a community and in the early years of Twitter, NephMadness was central to the formation of #NephTwitter and defining the ethos that makes our online community kind, intelligent, vibrant, and interesting. The NephMadness Podcrawl hopes to inspire and grow the nephrology podcast community in the same way. For 2023, our second year, the PodCrawl has assembled the Avengers of Medical Pods! Go to NephMadness.com/podcrawl for more information and links to all of the podcasts! The Curbsiders gets the skinny on mineralcorticoid receptor antagonists Core IM will be covering Kidney Transplant in their classic Five Pearl format The CardioNerds will be covering the effect of Heart Failure Devices on Kidney Health Freely Filtered will try to understand thrombotic microangiopathy ISN Global Kidney Care goes deep on IgA nephropathy The Cribsiders look at transitions, first the Peditrics to Adult nephrology transition and then from living to death with palliative nephrology Fellow on Call will be covering Onconephrology And finally, The Nephron Segment looks at Transgender Health and CKD

The Filtrate: Joel Topf Swapnil Hiremath Nayan Arora Sophia Ambruso With Special Guest: Amit Garg @AmitXGarg, Nephrologist at Western University, London, and lead PI of the MYTEMP trial. Editor: Joel Topf Show Notes: MyTEMP in pubmed: Personalised cooler dialysate for patients receiving maintenance haemodialysis (MyTEMP): a pragmatic, cluster-randomised trial MyTEMP Summary on NephJC It’s really cold in Ontario The NephTrials blog summary on Pragmatic Trials The pragmatic TiME trial on longer time on dialysis (ahem, sabotaged by site investigators like Joel who cut dialysate time) Dember et al in JASN Poor quality of trial data preceding MyTEMP, a systematic review from Mustafa et al in JASN The 2007 European Best Practice Guideline (EBPG) from 2007, recommending “Cool dialysate temperature dialysis (35–36°C) or isothermic treatments by blood temperature controlled feedback should be prescribed in patients with frequent episodes of IDH (Evidence level I).” in NDT 47% of centres from a DOPPS study of 273 centers routinely use of lower dialysate temperature, Dasgupta et al in JASN How do you convert from C to F? Almanac.com (35.5 C is 96.9 F; 37 C is 98.6 F) More on the rationale and design of MyTEMP: Al-Jaishi et al in CJKHD How big is 4.3 million (the number of hemodialysis treatments in MyTEMP)? Very big indeed. NephJC discussion of another cluster RCT and granular data only on a subset SSASS Participants in dialysis clinical trials are not representative of the real world dialysis cohorts, Smyth et al in JAMA Int Med Peritoneal dialysis numbers in Ontario are high, Blake et al in PDI, though with ~ 60% CVC rates, Blake et al in Kidney360 Dialysate Magnesium #DreamRCT from Swap, NephTrials discussion of DialMag Statistical analysis plan of MyTEMP, Dixon et al in CJKHD Tubular Secretions Swap: Watch Everything, Everywhere All At Once on Prime Nayan: Read The Midnight Ride from Ben Mezrich (brother of Josh Mezrich from the NephJC Summer Book Club 2021) Sophia: Making nephrology education fun at the UC Denver Amit: The wrestling team at Western U from 1990-91 Joel: House of the Dragon on HBO Max

The Filtrate: Joel Topf Swapnil Hiremath Jordy Cohen With Special Guest: Laurie Tomlinson. @Roxytonin Nephrologist at University Hospitals Sussex and research hero of Jordy. Editor: Priya Yenebere Show Notes: STOP-ACE in pubmed: Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease STOP-ACE Summary in NephJC Prior data showing preservation of renal function by stopping ACEi: The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease Efficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency: NEJM Dr. Tomlinson’s article on creatinine changes in RASi from 2017: Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study NephJC | PubMed Accuracy of eGFR at low GFR: A new equation to estimate glomerular filtration rate Strong opinions, loosely held. “Permissive AKI” with treatment of heart failure. Editorial by Chirag Parish and Steven Coca The rational for NICE avoiding RASi in black patients: Hypertension and ethnic group AASK trial showing superiority of RASi in African Americans. JAMA ALLHAT post-hoc analysis of outcomes by self-reported race. JAMA | PubMed Sophisticated Swedish observational study that Swap loved. Stopping Renin-Angiotensin System Inhibitors in Patients with Advanced CKD and Risk of Adverse Outcomes: A Nationwide Study Target Trials in Nephrology Dr Edouard Fu grand rounds at Ottawa Nephrology, YouTube Target Trial EmulationA Framework for Causal Inference From Observational Data by Miguel Hernán in JAMA Tubular Secretions Jordy: Third season of His Dark Materials on HBO Swap: Movies by Wes Anderson on Disney Plus Laurie: The Book, “Nearly All the Men in Lagos are Mad” Jordy: How Medicine Works and When It Doesn't: Learning Who to Trust to Get and Stay Healthy | Amazon Joel EO | NYT Review

The Filtrate: Joel Topf Swapnil Hiremath Josh Waitzman Sophia Ambruso Priya Yenebere With Special Guest: Brendon Neuen, Secretariat of the SGLT2 Trialists Consortium and cool guy on Twitter. Editor: Sophia Ambruso Show Notes: Joel’s Conflict of Interest Statement. Sophia is also conflicted with Astra Zeneca and Brendon with everybody in the SGLT2i space. Joel starts off with a history of SGLT2i EMPA-REG Outcomes. First! CANVAS. OMG this signal is reproducible! CREDENCE (🎧). It works in a dedicated population at high risk of kidney disease. And in a study designed for renal end-points. DAPA-CKD (🎧). It’s not just for diabetics! EMPA-Kidney. It works at really low GFR. And without albuminuria. And again in non-diabetics. SGLT Inhibitors for Type 1 Diabetes: Proceed With Extreme Caution Click to find the supplement (requires a subscription) Differences in definition in the decreased renal function component of the composite primary outcomes. EMPA-Kidney 40% DAPA-Kidney 50% CREDENCE doubling of serum Cr Usability Testing of a Sick-Day Protocol in CKD (Pubmed) New Guidelines for Statistical Reporting in the Journal (link, commentary on said guidelines by Frank Harrell) CKD outcomes and the FDA: Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency The Peripheral on Amazon Prime Unsealed the Tylenol Murders Podcast Project Hail Mary by Andrew Weir Lizzy McAlpine Singer Song Writer Rachel Maddow Presents: Ultra Twitter chaos continues. Get your Med-Mastodon handle

The Filtrate: Joel Topf Swapnil Hiremath Nayan Arora Sophia Ambruso Editor: Nayan Arora Show Notes: Joel’s Conflict of Interest Statement The Draft Board EMPA-Kidney is “off the board” Lunch Symposium on Current and Future Approaches to the Diagnostic Assessment and Management of AKI in Patients with Cirrhosis provided by an educational grant from Mallinckrodt Pharmaceuticals The CONFIRM Trial Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome in NephJC Clinical Practice Session Leveraging Social Media to Create, Learn, Teach, Advocate, and Dispel Misinformation The BEST-Fluids Trial: A Randomized Controlled Trial of Balanced Crystalloid Solution vs. Saline to Prevent Delayed Graft Function in Deceased Donor Kidney Transplantation - Michael G. Collins, Magid Fahim, Elaine Pascoe, Carmel Hawley, David W. Johnson, Philip A. Clayton, Steven J. Chadban (ClinicalTrials.gov) The Late Breaking and High Impact Trials Session line up Stop ACEi CLARITY Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial Effects of Pantoprazole on Kidney Outcomes: Post Hoc Analyses From the COMPASS Randomized Controlled Trial by Lonnie Pyne, et al No Stone: Hydrochlorothiazide for the Prevention of Kidney Stone Recurrence by Daniel Foster, et al MyTEMP: Personalised cooler dialysate for patients receiving maintenance haemodialysis (MyTEMP): a pragmatic, cluster-randomised trial Clinical Practice Session Best of NephJC “We'd Now Like To Open The Floor To Shorter speeches disguised as questions.” ASN Task Force on the Future of Nephrology Attracting Osteopathic Medical Students Into Nephrology Hasan Minhaj’s joke at the expense of DOs TRANSFORM-HF: Torsemide vs. Furosemide in Treating Patients With HF Point-of-Care Ultrasound in Nephrology specifically VExUS

The Filtrate: Joel Topf Jordy Cohen Nayan Arora Sophia Ambruso Special Guests: Boback Ziaeian @boback Assistant Professor of Medicine David Geffen School of Medicine at UCLA returns for his second episode (SODIUM-HF). His Google Schoolar page is better than yours. David Ellison @dhekidney is professor of medicine at Oregon Health Science University and head of the Oregon Clinical & Translational Institute. Show Notes: Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome (The CARESS Trial) Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure (The UNLOAD trial) Diuretic Strategies in Patients with Acute Decompensated Heart Failure (The DOSE Trial) Diuretic Strategies for Loop Diuretic Resistance in Acute Heart Failure (The 3T Trial) Sequential nephron blockade with a thiazide diuretic has a 1 B-NR (non-radomized) grade in the AHA/ACC Heart Failure Guidelines (7.2) Three important acute decompensated heart failure with SGLT2i: 1. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure (SOLOIST-WHF Trial) 2. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial (The EMPULSE Trial) 3. Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF) Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care: JACC State-of-the-Art Review Cardiologist Sues Epic Over Copyright Infringement Outcomes associated with a strategy of adjuvant metolazone or high-dose loop diuretics in acute decompensated heart failure: a propensity analysis. Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance (PubMed) Efficacy and Safety of Spironolactone in Acute Heart Failure (ATHENA Trial) Joel with a video on acetazolamide for altitude sickness. The Butchering Art: Joseph Lister's Quest to Transform the Grisly World of Victorian Medicine(Amazon)

The Filtrate: Joel Topf Swapnil Hiremath Nayan Arora Priya Yenebere Special Guests: Todd Miano, PharmD, PhD @Miano81 Assistant Professor of Epidemiology, Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine. Show Notes: Early Pip/Tazo article showing nephrotoxicity. Covered by NephJC Linazolid vs Vanco RCT showing excess AKI with Vanco. Yes Vance is a lot less toxic than it was in the Mississippi mud days but your attending telling you it is no longer nephrotoxic is wrong. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study and Vancomycin and the Risk of AKI: A Systematic Review and Meta-Analysis. Vancomycin-Associated Acute Kidney Injury with a Steep Rise in Serum Creatinine Vancomycin-Associated Cast Nephropathy: Reality or Fantasy? Molecular Epidemiology of SepsiS in the ICU (MESSI) prospective cohort. Learn about it her: A multibiomarker-based outcome risk stratification model for adult septic shock* Cystatin C in acute kidney injury Changing Definitions of Sepsis Proposed new definitions of AKI incorporating biomarkers: Recommendations on Acute Kidney Injury Biomarkers From the Acute Disease Quality Initiative Consensus Conference. A Consensus Statement in JAMA Network Open Applications of propensity score methods in observational comparative effectiveness and safety research: where have we come and where should we go? The effect of glucocorticoids on serum cystatin C in identifying acute kidney injury: a propensity-matched cohort study Protective effect of piperacillin against nephrotoxicity of cephaloridine and gentamicin in animals PulmCrit – Myth-busting the conditional nephrotoxicity of piperacillin-tazobactam by Josh Farkas Sharp Objects on Good Reads Bandon Dunes The Ocean Course at Kiawah Island Golf Resort Be Real follow me: BeRe.al/kidney_boy SNL spoof of BeReal